Dongkuk Pharmaceutical Signs Exclusive Sales Agreement With Samyang Holdings, NikoStop, Rheumatop Power Plasta
Aug 18, 2025
Dongguk Pharmaceutical and Samyang Holdings Biopharmaceuticals Group have signed a joint promotion contract for over-the-counter drugs 'nicostop' and 'RyuMastop Power Plasta'. Samyang Holdings is in charge of product supply, while Dongkuk Pharmaceutical is in charge of exclusive domestic sales.
Launched in 1997, Nicostab is a nicotine replacement therapy (NRT) product that has been proven effective and safe over a long period of 28 years. The concentration of nicotine in the blood is kept constant for 24 hours, effectively suppressing withdrawal symptoms and smoking desire, and minimizing skin irritation by optimizing nicotine usage and size. It had a 57% nicotine patch market share in 2022 (based on IQVIA data) and also ranked first in brand recognition (non-smoking supplement nicotine patch segment) in Hankook Research's Consumer Survey in 2024. Depending on nicotine content, it consists of 30 patches (42 mg), 20 patches (28 mg), and 10 patches (14 mg) products, and is expected to be included in the smoking cessation education program of health centers nationwide, increasing their utilization in the public sector. Through this joint promotion, Dongkuk Pharmaceutical will enter the health center distribution channel in earnest.
In addition to Nicostap, the two companies will also develop a joint promotion of Rheumatop Powerplasta that helps relieve joint and muscle pain.
Rheumatoid anti-inflammatory analgesics (NSAIDs), which were launched in 1998 and have built trust in terms of drug effectiveness and safety for 27 years, contain the highest content (70 mg) of diclophenac among pain relief products currently released in the market.
A Dongkuk Pharmaceutical official said "It is expected that Samyang Holdings BioPharm Group's differentiated patch technology and Dongkuk Pharmaceutical's strong OTC capabilities will meet to create great synergy."
Launched in 1997, Nicostab is a nicotine replacement therapy (NRT) product that has been proven effective and safe over a long period of 28 years. The concentration of nicotine in the blood is kept constant for 24 hours, effectively suppressing withdrawal symptoms and smoking desire, and minimizing skin irritation by optimizing nicotine usage and size. It had a 57% nicotine patch market share in 2022 (based on IQVIA data) and also ranked first in brand recognition (non-smoking supplement nicotine patch segment) in Hankook Research's Consumer Survey in 2024. Depending on nicotine content, it consists of 30 patches (42 mg), 20 patches (28 mg), and 10 patches (14 mg) products, and is expected to be included in the smoking cessation education program of health centers nationwide, increasing their utilization in the public sector. Through this joint promotion, Dongkuk Pharmaceutical will enter the health center distribution channel in earnest.
In addition to Nicostap, the two companies will also develop a joint promotion of Rheumatop Powerplasta that helps relieve joint and muscle pain.
Rheumatoid anti-inflammatory analgesics (NSAIDs), which were launched in 1998 and have built trust in terms of drug effectiveness and safety for 27 years, contain the highest content (70 mg) of diclophenac among pain relief products currently released in the market.
A Dongkuk Pharmaceutical official said "It is expected that Samyang Holdings BioPharm Group's differentiated patch technology and Dongkuk Pharmaceutical's strong OTC capabilities will meet to create great synergy."
|
This article was translated by Naver AI translator.
